Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 2, 2026
Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Fineline Cube Mar 2, 2026
Company Drug

Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program

Fineline Cube Dec 5, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...

Company Drug

Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003

Fineline Cube Dec 5, 2022

China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...

Company Deals

Lavamed Secures USD 40M in Angel and Series A Financing Rounds

Fineline Cube Dec 5, 2022

Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...

Company Drug

Innovent Biologics Doses First Volunteer in Orismilast Phase I Study

Fineline Cube Dec 5, 2022

China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...

Company Drug

Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study

Fineline Cube Dec 5, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...

Company Deals

Tsingke Biotech Secures RMB 400M Series B Financing for Expansion

Fineline Cube Dec 5, 2022

Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB...

Company Deals

China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia

Fineline Cube Dec 5, 2022

China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...

Company Deals

SAFE Raises RMB 500M in Series D Financing to Expand CRO Services

Fineline Cube Dec 5, 2022

Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy...

Company Medical Device

Peijia Medical Enrolls First Patient in GeminiOne TEER System Study

Fineline Cube Dec 5, 2022

China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study...

Company Drug

NMPA Approves Henlius’ HLX04 Biosimilar for Lung and Colorectal Cancer

Fineline Cube Dec 2, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Shanghai Henlius Biotech’s (HKG: 2696)...

Company Deals

Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha

Fineline Cube Dec 2, 2022

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in...

Company Drug

Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials

Fineline Cube Dec 2, 2022

China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...

Company Deals

Eli Lilly Ends License for Innovent’s Tyvyt Outside China

Fineline Cube Dec 2, 2022

Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...

Company Deals

Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China

Fineline Cube Dec 2, 2022

Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...

Company Deals Digital

Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine

Fineline Cube Dec 2, 2022

China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...

Company Deals

Pediatrix Therapeutics Licenses Tris Pharma’s ADHD Portfolio for Greater China

Fineline Cube Dec 2, 2022

China-based Pediatrix Therapeutics announced a licensing agreement with US firm Tris Pharma, Inc., obtaining exclusive...

Policy / Regulatory

Hainan’s New Regulations on Medical Devices in Boao Lecheng to Take Effect in 2023

Fineline Cube Dec 2, 2022

The “Regulations on the Administration of Medical Devices in Boao Lecheng International Medical Tourism Pilot...

Company Drug

Kintor’s KX-826 Reaches Primary Endpoint in Phase II Study for Female AGA

Fineline Cube Dec 2, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced that the Phase II clinical study for its...

Company Medical Device

Sansure Biotech’s Pertussis Detection Kit Approved by NMPA

Fineline Cube Dec 2, 2022

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced that it has obtained medical...

Company Drug

Simcere’s Edaravone, Borneol Sublingual Tablets Reach Phase III Efficacy Endpoint

Fineline Cube Dec 2, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that a Phase III clinical study for...

Posts pagination

1 … 554 555 556 … 628

Recent updates

  • Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy
  • HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline
  • Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.